No benefit seen in primary end point of median clonal growth rate, but benefits seen in terms of secondary outcomes
MONDAY, Sept. 21, 2026 (HealthDay News) — For patients with clonal cytopenia of undetermined significance (CCUS) or lower-risk myeloid malignancies, oral vitamin C is safe and biologically active, according to a study published online Sept. 21 in Cancer.
Stine Ulrik Mikkelsen, M.D., Ph.D., from Copenhagen University Hospital-Rigshospitalet in Denmark, and colleagues conducted a double-blind, randomized, placebo-controlled, phase 2 trial involving adults with CCUS or lower-risk myeloid malignancies not receiving anticancer therapy. Participants were randomly assigned to receive oral vitamin C (1,000 mg/day) or placebo for 12 months (55 and 54 participants, respectively).
The researchers observed no significant difference between the groups in the primary end point of median clonal growth rate, but secondary outcomes included differences in inflammatory cytokine trajectories and fewer serious adverse events in the vitamin C group versus placebo group (33 versus 57 percent). Overall survival was significantly longer with vitamin C in an exploratory analysis (hazard ratio, 0.35).
“We are encouraged by our findings and what they ultimately could mean for people with these early-stage blood disorders,” co-senior author Kirsten Grønbæk, M.D., Ph.D., also from Rigshospitalet, said in a statement. “Although it is too soon to make recommendations based on our results, we are hopeful that a larger study will give us more definitive answers.”
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Reference Intervals Developed for Children, Adults With Duffy Null Status
Genetic Screening Can ID Hemoglobinopathy Prevalence
Serum 25(OH)D May Serve as Biomarker of Disease Activity in IBD
Family History of CRC Increases CRC Risk Similarly in IBD, General Population
Healthy Lifestyle in Early Childhood Linked to Lower Risk for IBD
Most Adults With Moderate-to-Severe Ulcerative Colitis Ineligible for RCTs
Bowel Urgency in Ulcerative Colitis Linked to Disease-Related Disability